首页> 外文OA文献 >Dose Effect of Dual Delivery of Vascular Endothelial Growth Factor and Bone Morphogenetic Protein-2 on Bone Regeneration in a Rat Critical-Size Defect Model
【2h】

Dose Effect of Dual Delivery of Vascular Endothelial Growth Factor and Bone Morphogenetic Protein-2 on Bone Regeneration in a Rat Critical-Size Defect Model

机译:大鼠临界大小缺损模型中血管内皮生长因子和骨形态发生蛋白2双重递送对骨再生的剂量效应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The dose effect of dual delivery of vascular endothelial growth factor (VEGF) and bone morphogenetic protein-2 (BMP-2) on bone regeneration was investigated in a rat cranial critical-size defect (CSD). It was hypothesized that decreasing amounts of BMP-2 would result in a dose-dependent decrease in bone formation, and that this reduction in bone formation could be reversed by adding increasing amounts of VEGF. In vitro release kinetics of VEGF or BMP-2 were examined over 28 days. Next, scaffolds were implanted within a rat cranial CSD containing different combinations of both BMP-2 and VEGF. At 12 weeks, samples were analyzed using microcomputed tomography and histology. In vitro, VEGF and BMP-2 exhibited burst release in the first 24 h followed by a significant decrease in release rate over 27 days. Overall, BMP-2 had a more sustained release versus VEGF. An in vivo dose-dependent decrease in percentage of bone fill (PBF) was observed for BMP-2. The addition of VEGF was unable to reverse this decrease in PBF, although improvements in the number of bridged defects did occur in some groups. This suggests that for this particular model simultaneous release of BMP-2 and VEGF does not increase bone formation over BMP-2 alone at 12 weeks.
机译:在大鼠颅骨临界大小缺损(CSD)中,研究了血管内皮生长因子(VEGF)和骨形态发生蛋白2(BMP-2)双重递送对骨再生的剂量效应。假设减少BMP-2的量将导致骨形成的剂量依赖性减少,并且通过增加VEGF的量可以逆转这种骨形成的减少。在28天内检查了VEGF或BMP-2的体外释放动力学。接下来,将支架植入包含BMP-2和VEGF的不同组合的大鼠颅CSD中。在第12周,使用微型计算机断层扫描和组织学分析样品。在体外,VEGF和BMP-2在最初的24小时内表现出爆发释放,随后在27天内释放速率显着下降。总体而言,BMP-2与VEGF相比具有更持久的释放。对于BMP-2,观察到了体内剂量依赖性骨填充(PBF)百分比的降低。尽管某些组确实确实改善了桥接缺陷的数量,但添加VEGF不能逆转PBF的下降。这表明对于该特定模型,与单独使用BMP-2相比,在12周时BMP-2和VEGF的同时释放不会增加骨形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号